WO2001012607A3 - Compositions pharmaceutiques comprenant des 4-quinolones pour le traitement des cancers - Google Patents

Compositions pharmaceutiques comprenant des 4-quinolones pour le traitement des cancers Download PDF

Info

Publication number
WO2001012607A3
WO2001012607A3 PCT/FR2000/002310 FR0002310W WO0112607A3 WO 2001012607 A3 WO2001012607 A3 WO 2001012607A3 FR 0002310 W FR0002310 W FR 0002310W WO 0112607 A3 WO0112607 A3 WO 0112607A3
Authority
WO
WIPO (PCT)
Prior art keywords
quinolones
pharmaceutical compositions
treating cancers
r6aare
proliferation
Prior art date
Application number
PCT/FR2000/002310
Other languages
English (en)
Other versions
WO2001012607B1 (fr
WO2001012607A2 (fr
Inventor
Benoit Joseph
Francis Darro
Gerald Guillaumet
Robert Kiss
Armand Frydman
Original Assignee
Lafon Labor
Benoit Joseph
Francis Darro
Gerald Guillaumet
Robert Kiss
Armand Frydman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lafon Labor, Benoit Joseph, Francis Darro, Gerald Guillaumet, Robert Kiss, Armand Frydman filed Critical Lafon Labor
Priority to EP00958676A priority Critical patent/EP1202971A2/fr
Priority to US10/049,512 priority patent/US6645983B1/en
Priority to CA002381968A priority patent/CA2381968A1/fr
Priority to IL14810600A priority patent/IL148106A0/xx
Priority to AU70122/00A priority patent/AU7012200A/en
Publication of WO2001012607A2 publication Critical patent/WO2001012607A2/fr
Publication of WO2001012607A3 publication Critical patent/WO2001012607A3/fr
Publication of WO2001012607B1 publication Critical patent/WO2001012607B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique non cytotoxique ayant une activité sur la prolifération de cellules clonogènes dans les tumeurs malignes et qui comprend une quantité efficace d'un composé choisi parmi les composés de formules (I) et (Ia) dans laquelle R1, R2, R3, R4, R5, R6 et R6a sont tels que définis à la revendication 1.
PCT/FR2000/002310 1999-08-13 2000-08-11 Compositions pharmaceutiques comprenant des 4-quinolones pour le traitement des cancers WO2001012607A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00958676A EP1202971A2 (fr) 1999-08-13 2000-08-11 Compositions pharmaceutiques comprenant des 4-quinolones pour le traitement des cancers
US10/049,512 US6645983B1 (en) 1999-08-13 2000-08-11 Pharmaceutical compositions comprising 4-quinolones for treating cancers
CA002381968A CA2381968A1 (fr) 1999-08-13 2000-08-11 Compositions pharmaceutiques comprenant des 4-quinolones pour le traitement des cancers
IL14810600A IL148106A0 (en) 1999-08-13 2000-08-11 Pharmaceutical compositions comprising 4-quinolones
AU70122/00A AU7012200A (en) 1999-08-13 2000-08-11 Pharmaceutical compositions comprising 4-quinolones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9910492A FR2797444B1 (fr) 1999-08-13 1999-08-13 Compositions pharmaceutiques comprenant des 4-quinolones
FR99/10492 1999-08-13

Publications (3)

Publication Number Publication Date
WO2001012607A2 WO2001012607A2 (fr) 2001-02-22
WO2001012607A3 true WO2001012607A3 (fr) 2001-05-03
WO2001012607B1 WO2001012607B1 (fr) 2001-11-22

Family

ID=9549145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/002310 WO2001012607A2 (fr) 1999-08-13 2000-08-11 Compositions pharmaceutiques comprenant des 4-quinolones pour le traitement des cancers

Country Status (7)

Country Link
US (1) US6645983B1 (fr)
EP (1) EP1202971A2 (fr)
AU (1) AU7012200A (fr)
CA (1) CA2381968A1 (fr)
FR (1) FR2797444B1 (fr)
IL (1) IL148106A0 (fr)
WO (1) WO2001012607A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
AU2004224788A1 (en) * 2003-03-26 2004-10-07 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
EP1732541A4 (fr) 2004-04-07 2008-03-05 Takeda Pharmaceutical Composes cycliques
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
US8598354B2 (en) 2008-12-05 2013-12-03 University Of South Florida Compounds having antiparasitic or anti-infectious activity
WO2010064701A1 (fr) 2008-12-05 2010-06-10 大塚製薬株式会社 Agent pharmaceutique comprenant un composé de quinolone
TWI492943B (zh) 2008-12-05 2015-07-21 大塚製藥股份有限公司 喹啉酮化合物及藥學組成物（二）
JP5769504B2 (ja) * 2010-06-04 2015-08-26 大塚製薬株式会社 医薬
CN105017145B (zh) * 2012-12-12 2017-12-05 王子厚 具有抗肿瘤活性的氯氧喹衍生物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002145A2 (fr) * 1992-07-22 1994-02-03 Genelabs Technologies, Inc. 2-aryl-4-quinolones utilisees comme composes antitumoraux
US5726184A (en) * 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
WO1998017662A1 (fr) * 1996-10-18 1998-04-30 Novartis Ag Derives d'heterocyclyle bicyclique a substitution phenyle et utilisation de ces derives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002145A2 (fr) * 1992-07-22 1994-02-03 Genelabs Technologies, Inc. 2-aryl-4-quinolones utilisees comme composes antitumoraux
US5726184A (en) * 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
WO1998017662A1 (fr) * 1996-10-18 1998-04-30 Novartis Ag Derives d'heterocyclyle bicyclique a substitution phenyle et utilisation de ces derives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOPUXUE ZAZHI, vol. 16, no. 2, - 1999, pages 169 - 172 *
CHEMICAL ABSTRACTS, vol. 131, no. 4, 26 July 1999, Columbus, Ohio, US; abstract no. 44554m, XU, MINGXIA ET AL.: "1H NMR of 3-phenyl-4(1H)-quinolone derivatives." XP002136387 *
DATABASE CHEMICAL ABSTRACTS XP002136390 *

Also Published As

Publication number Publication date
IL148106A0 (en) 2002-09-12
WO2001012607B1 (fr) 2001-11-22
CA2381968A1 (fr) 2001-02-22
WO2001012607A2 (fr) 2001-02-22
AU7012200A (en) 2001-03-13
FR2797444A1 (fr) 2001-02-16
US6645983B1 (en) 2003-11-11
FR2797444B1 (fr) 2003-02-07
EP1202971A2 (fr) 2002-05-08

Similar Documents

Publication Publication Date Title
IL140437A0 (en) Pharmaceutical compositions comprising 2-quinolines
GEP20043241B (en) Compounds for Treatment of Ischemia and Pharmaceutical Compositions Containing the Same
PL348451A1 (en) Glycopeptide derivatives and pharmaceutical compositions containing the same
BG105784A (en) Triazole compounds with dopamine-d3-receptor affinity
MY121397A (en) Ziprasidone formulations
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
GEP20043250B (en) Use of Indolyl-3-Glyoxylic Acid Derivatives as Anti-tumor Means and Pharmaceutical Compositions Containing the Same
WO2002094020A8 (fr) Utilisation de derives de triazolopyrimidine en tant que microbicides pour la protection de materiel
BG105731A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
IL136558A0 (en) Heterocyclic cytotoxic agents
WO2001012607A3 (fr) Compositions pharmaceutiques comprenant des 4-quinolones pour le traitement des cancers
PL313078A1 (en) Novel bis-naphtalimides for use in treating carcinoma
AU5390900A (en) Potassium channel blocking agents
IL134592A0 (en) Compositions comprising camptothecin compounds for the treatment of cancer with reduced side effects
AU3410099A (en) Pharmaceutical compositions containing melatonin inclusion complexes
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
CA2421008A1 (fr) Composes heterocycliques substitues destines au traitement de la resistance pleiotrope
YU46302A (sh) Supstituisani piroli
WO2000030587A3 (fr) INHIBITEURS DE L'ACTIVATION DE NF-λB, ET LEURS UTILISATIONS PHARMACEUTIQUES
AU5825100A (en) Nitrates of bis-platinum complexes with polyamine ligands
WO2001012632A3 (fr) Derives de phenanthroline-7-ones et leurs applications en therapeutique
IL149749A0 (en) N-(1-phenylethyl)-5-phenylimidazole-2-amine compounds, their compositions and uses
WO2001000240A3 (fr) Compose antitumoral
AU2002224431A1 (en) 2-substituted heterocyclic compounds and their use in treating multidrug resistance
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: 2000958676

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 148106

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2381968

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10049512

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000958676

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000958676

Country of ref document: EP